Literature DB >> 11073939

CD154 variant lacking tumor necrosis factor homologous domain inhibits cell surface expression of wild-type protein.

L Su1, E A Garber, Y M Hsu.   

Abstract

X-linked hyper-IgM (XHIM) syndrome is an immunological disorder resulting from mutations in the CD154 gene. Some mutations occur in splicing sites and result in transcripts encoding wild-type and mutant proteins. These mutants lack the tumor necrosis factor homologous (TNFH) domain and consequently fail to trimerize. Given that the TNFH domain is responsible for trimerization, one may predict that the TNFH mutant can not participate in the assembly of wild-type CD154. Thus, it was puzzling why these patients exhibit XHIM phenotype, presumably resulting from a lack of functional CD154. One possibility is that the TNFH mutant exhibits a dominant negative effect over the wild-type protein. To investigate this, we coexpressed the wild-type protein and a TNFH mutant and examined the biochemical and functional properties of the resulting CD154 products. We demonstrate that despite the lack of the TNFH domain, the TNFH mutant can associate with the wild-type protein. Furthermore, such an association compromises the ability of the wild-type protein to mature onto the cell surface. These results provide a mechanism for the defect of CD154 in XHIM patients producing both wild-type and TNFH variants and suggest that besides the TNFH domain, the stalk region participates in the assembly of CD154 trimers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073939     DOI: 10.1074/jbc.C000674200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics.

Authors:  Tábata Takahashi França; Lucila Akune Barreiros; Ranieri Coelho Salgado; Sarah Maria da Silva Napoleão; Lillian Nunes Gomes; Janáira Fernandes Severo Ferreira; Carolina Prando; Cristina Worm Weber; Regina Sumiko Watanabe Di Gesu; Cecilia Montenegro; Carolina Sanchez Aranda; Gisele Kuntze; Aidé Tamara Staines-Boone; Edna Venegas-Montoya; Juan Carlos Aldave Becerra; Liliana Bezrodnik; Daniela Di Giovanni; Ileana Moreira; Gisela Analia Seminario; Andrea Cecilia Gómez Raccio; Mayra de Barros Dorna; Nelson Augusto Rosário-Filho; Herberto Jose Chong-Neto; Elisa de Carvalho; Milena Baptistella Grotta; Julio Cesar Orellana; Miguel Garcia Dominguez; Oscar Porras; Laura Sasia; Karina Salvucci; Emilio Garip; Luiz Fernando Bacarini Leite; Wilma Carvalho Neves Forte; Fernanda Pinto-Mariz; Ekaterini Goudouris; María Enriqueta Nuñez Nuñez; Magdalena Schelotto; Laura Berrón Ruiz; Diana Inés Liberatore; Hans D Ochs; Otavio Cabral-Marques; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2022-01-04       Impact factor: 8.317

2.  Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM.

Authors:  K C Gilmour; D Walshe; S Heath; G Monaghan; S Loughlin; T Lester; G Norbury; C M Cale
Journal:  Mol Pathol       Date:  2003-10

3.  Genetically targeted adenovirus vector directed to CD40-expressing cells.

Authors:  Natalya Belousova; Nikolay Korokhov; Valentina Krendelshchikova; Vera Simonenko; Galina Mikheeva; Pierre L Triozzi; Wayne A Aldrich; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Three novel mutations reflect the variety of defects causing phenotypically diverse X-linked hyper-IgM syndrome.

Authors:  E López-Granados; R Cambronero; A Ferreira; G Fontán; M C García-Rodríguez
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.